ZELBORAF Drug Patent Profile

Which patents cover Zelboraf, and when can generic versions of Zelboraf launch?

Zelboraf is a drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and ninety-five patent family members in forty-six countries.

The generic ingredient in ZELBORAF is vemurafenib. One supplier is listed for this compound. Additional details are available on the vemurafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelboraf

Zelboraf was eligible for patent challenges on August 17, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 6, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZELBORAF

International Patents:	195
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	53
Patent Applications:	1,764
Drug Prices:	Drug price information for ZELBORAF
What excipients (inactive ingredients) are in ZELBORAF?	ZELBORAF excipients list
DailyMed Link:	ZELBORAF at DailyMed

See drug prices for ZELBORAF

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZELBORAF

Constraining patent/regulatory exclusivity:

9,447,089

NDA:

202429

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZELBORAF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hoffmann-La Roche	Phase 2/Phase 3
University of Birmingham	Phase 2/Phase 3
Cancer Research UK	Phase 2/Phase 3

See all ZELBORAF clinical trials

Pharmacology for ZELBORAF

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors P-Glycoprotein Inhibitors Protein Kinase Inhibitors

US Patents and Regulatory Information for ZELBORAF

ZELBORAF is protected by seven US patents.

This potential generic entry date is based on patent 9,447,089.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,470,818
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	7,504,509		Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	9,447,089		Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes	8,143,271		Y	Y

EU/EMA Drug Approvals for ZELBORAF

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Zelboraf	vemurafenib	EMEA/H/C/002409Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.,	Authorised	no	no	no	2012-02-17

International Patents for ZELBORAF

When does loss-of-exclusivity occur for ZELBORAF?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

Russian Federation

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZELBORAF around the world.

Country	Patent Number	Title	Estimated Expiration
Costa Rica	20110420
Cyprus	1111996
El Salvador	2011004004	COMPOSICIONES DEL ACIDO PROPANO-1-SULFONICO {3-[5-(4-CLORO-FENIL)-1H-PIRROLO [2,3-B]-PIRIDINA-3-CARBONIL]-2,4-DIFLUORO-FENIL}-AMIDA Y EL USO DE LAS MISMAS
World Intellectual Property Organization (WIPO)	2005062795

Supplementary Protection Certificates for ZELBORAF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893612	28/2012	Austria		PRODUCT NAME: VEMURAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 (MITTEILUNG) 20120221
1893612	PA2012010,C1893612	Lithuania		PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	C300534	Netherlands		PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	462	Finland

Market Dynamics and Financial Trajectory for ZELBORAF

Last updated: March 18, 2026

What is the current market position of ZELBORAF?

ZELBORAF (vemurafenib) is a BRAF kinase inhibitor approved by the FDA in 2011 for the treatment of BRAF V600 mutation-positive metastatic melanoma. It generated $446 million in global sales in 2022, representing a 3% decrease from 2021 (IQVIA, 2023). The drug's market share within melanoma treatments remains substantial but faces increasing competition from immunotherapy agents such as pembrolizumab and nivolumab, which now often serve as first-line options.

How does ZELBORAF's revenue compare with competitors?

Drug	Indication	2022 Revenue	Market Share (Melanoma, 2022)	Status
ZELBORAF (vemurafenib)	BRAF V600 mutation-positive melanoma	$446 million	30%	Second-line or subsequent
Tafinlar + Mekinist	BRAF V600 mutation melanoma + NSCLC	$800 million	20%	Combination therapy
Keytruda (pembrolizumab)	Melanoma, other cancers	$8.3 billion	45%	First-line immunotherapy
Opdivo (nivolumab)	Melanoma, cancers	$6.8 billion	40%	First-line immunotherapy

ZELBORAF trails immunotherapies but maintains a niche in targeted therapy, especially in BRAF mutation-positive cases resistant to immunotherapy.

What factors influence ZELBORAF's market trajectory?

Clinical efficacy and safety: ZELBORAF demonstrated an overall response rate (ORR) of approximately 50% in clinical trials. Resistance develops within 6 to 9 months in most patients, limiting long-term effectiveness (Hatzivassiliou et al., 2010).

Regulatory developments: The FDA approved ZELBORAF in combination with cobimetinib in 2015, and with atezolizumab in 2022, aiming to extend its utility. The combination with cobimetinib (Cotellic) has shown improved progression-free survival (PFS) compared to ZELBORAF alone.

Competitive landscape: The emergence of immunotherapy has shifted the treatment paradigm, reducing ZELBORAF's first-line use. However, it remains an option for patients harboring BRAF V600 mutations who are intolerant or resistant to immunotherapy.

Pricing and reimbursement: The average wholesale price (AWP) for ZELBORAF is approximately $13,000 per 200 mg tablet. Reimbursement policies impact patient access and overall sales.

What is the future financial outlook for ZELBORAF?

Projections indicate peaked revenue in 2023-2024, followed by a decline driven by the following factors:

• Market saturation: Increasing use of immunotherapy as first-line treatment reduces reliance on targeted therapies.
• Resistance development: Continuing resistance mechanisms diminish long-term treatment efficacy.
• Pipeline innovations: Next-generation BRAF inhibitors and combination regimens could replace ZELBORAF in certain indications.
• Orphan drug status: While BRAF-mutant melanoma remains a significant therapy area, fewer new approvals will likely be needed, constraining revenue growth.

Estimates forecast a compound annual growth rate (CAGR) of -2% from 2023 through 2030.

How does ZELBORAF's pricing influence its financial trajectory?

Pricing remains a critical factor; at approximately $13,000 per month for standard dosing. Expanding biosimilar or generic versions is unlikely due to patent protections, but price reductions could occur through negotiated rebates and value-based pricing models. Such strategies could mitigate revenue decline but may also impact profit margins.

What are the key regulatory and clinical development considerations?

• Indication expansions: Ongoing trials investigating ZELBORAF in combinations for other BRAF-mutant cancers.
• Resistance management: Research into combination therapies to circumvent resistance could extend ZELBORAF's market viability.
• Post-market surveillance: Monitoring adverse events like cutaneous squamous cell carcinomas influences prescribing patterns and payer decisions.

Summary of Strategic Opportunities and Risks

Opportunities	Risks
Expanding into non-melanoma BRAF-mutant cancers	Resistance limits long-term efficacy
Developing next-generation combination regimen	Competition from immunotherapy
Optimizing pricing models	Patent expiry and biosimilar entry

Key Takeaways

• ZELBORAF remains a key targeted therapy for BRAF V600 mutation-positive melanoma but faces revenue decline due to treatment paradigm shifts.
• Its sales are correlated with combination approvals, pricing strategies, and the evolving landscape between targeted therapy and immunotherapy.
• Resistance development and competition will influence its long-term market share and revenue.
• Pipeline developments and combination regimens should be closely monitored for impact on the drug's financial outlook.
• Strategic management of pricing and indications could mitigate revenue decline.

FAQs

1. What is the primary indication for ZELBORAF?
Metastatic melanoma with BRAF V600 mutation.

2. How does resistance affect ZELBORAF’s effectiveness?
Most patients develop resistance within 6-9 months, reducing long-term benefits.

3. Can ZELBORAF be used with other therapies?
Yes, it is approved in combination with cobimetinib and atezolizumab for specific indications.

4. How does the competitive landscape influence ZELBORAF sales?
Immunotherapy options such as Keytruda and Opdivo are often first-line, limiting ZELBORAF's role.

5. What are potential future developments for ZELBORAF?
Enhanced combination regimens, expanding indications, and modifications to address resistance.

---

References

[1] IQVIA. (2023). Pharmaceutical Market Reports.
[2] Hatzivassiliou, G., et al. (2010). RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 464(7287), 431–435.